Day

Quick links to important sections

Day

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Day

Quick Facts

Property Description
Active ingredient Acetaminophen (Paracetamol)
Form Tablet, Capsule, Solution, Suppository
Pharmacological class Non-opioid Analgesic, Antipyretic
Common use Relief of mild to moderate pain and fever
Origin Synthetic compound

What is Day and Its Pharmacological Classification?

The proprietary medication Day is a highly defined medicinal product containing Acetaminophen, which is internationally recognized by the name Paracetamol. It is strictly classified as a non-opioid analgesic and an antipyretic agent, meaning its core function is to relieve pain and reduce fever. This dual action corresponds to the substance's recognized ability to alleviate pain and reduce elevated body temperature.

The medicine is a synthetic compound and is fundamentally distinct from NSAIDs (Nonsteroidal Anti-inflammatory Drugs), as its primary mechanism does not produce significant anti-inflammatory effects throughout the body. Paracetamol is widely recognized as an essential medicine, confirming its broad utility for essential symptomatic care globally, such as temporary relief during a flu or cold episode.


Composition, Forms, and General Therapeutic Purpose

Day is typically available as a single-active ingredient product, composed of Acetaminophen and inert pharmaceutical excipient bases. This composition allows for delivery via multiple dosage forms, including traditional tablets, capsules, liquid solutions, and suppositories, facilitating flexible oral or rectal administration.

While often used in its singular form to target only pain and fever, the product is also integrated into combination products alongside other ingredients to address wider symptom complexes. In any form, its primary general therapeutic purpose remains consistent: to help individuals manage temporary discomfort and restore their body temperature to a normal state by acting centrally on the brain’s regulatory systems.

Regulatory References

  1. supported by the National Library of Medicine (NIH)

What side effects are possible with Day?

Possible Side Effects and Safety Information

The safety profile for Day (Acetaminophen/Paracetamol) is defined by government regulatory documents, which classify potential effects by frequency and physiological system. The adverse reactions are categorized using standard regulatory terminology (e.g., Common, Uncommon, Rare, Not Known) to communicate the likelihood of documented events.

Regulatory Frequency Example System-Organ Class Effects
Common Gastrointestinal Disorders (Nausea, Vomiting)
Uncommon Skin and Subcutaneous Tissue Disorders (Skin rash, Itching)
Very Rare Severe Skin Reactions (SJS, TEN, AGEP)

The most significant safety concern documented by authorities such as the FDA and EMA is Hepatotoxicity (severe liver damage or acute liver failure). This risk is primarily associated with exceeding the maximum daily dose or the concurrent use of multiple products containing the active ingredient. The safety labeling strictly defines this risk as a potential serious adverse reaction.

Safety Constraints and Special Populations

The official labeling includes safety constraints that restrict use in certain situations. The medicine is contraindicated in individuals with known hypersensitivity to the active substance or its excipients. Furthermore, specific caution and constraints are noted for special populations:

  • Severe Hepatic Impairment: The medicine is generally contraindicated in cases of severe liver insufficiency.
  • Chronic Alcoholism: Individuals consuming three or more alcoholic drinks daily are documented as being at greater risk of hepatotoxicity.
  • Severe Renal Impairment: Caution is necessary in patients with severe kidney function impairment (e.g., creatinine clearance le 30 mL/min).

The safety profile emphasizes that adherence to the maximum daily limit is the primary documented safeguard against the most serious adverse outcomes.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that overdose is a serious medical event that requires immediate intervention, even if symptoms are not initially severe. The primary danger of Day (Acetaminophen/Paracetamol) overdose is the potential for severe liver damage (hepatic necrosis), which can lead to acute liver failure and may be fatal. This outcome is dose-dependent and necessitates urgent management.

Documented Manifestations and Actions

Classification Regulatory Statements
Early Symptoms Non-specific signs may include pallor, nausea, vomiting, anorexia, abdominal pain, and sweating.
Severe Outcomes Delayed symptoms (48 to 72 hours) include jaundice, confusion, coma, and acute renal failure (which can occur without severe liver injury).
High-Risk Groups Patients with chronic alcoholism, pre-existing hepatic disease, or chronic malnutrition are documented to be at increased risk of severe toxicity.
Immediate Action Immediate medical advice must be sought and patients must be referred to a hospital urgently, even if they appear well, due to the risk of delayed, severe consequences.

Management procedures described in official labels focus on symptomatic and supportive treatment, including decontamination measures such as gastric lavage. The specific antidote, N-acetylcysteine, is documented and its effectiveness is greatest when administered within the first 8 to 10 hours post-ingestion.

Therapeutic Uses of Day

Day (Acetaminophen/Paracetamol) is widely applied for supportive symptomatic assistance across therapeutic domains involving heightened patient discomfort, primarily targeting pain and fever. The medication is applied for easing mild to moderate pain and reducing fever, supporting patients during episodes of heightened symptoms.

Core Symptom Relief

Day helps address symptom clusters that may become intense or disruptive, including tension headaches, dental discomfort, musculoskeletal aches, and menstrual pain. The medication's role is to provide supportive relief that contributes to easing the overall symptom load, and may help support general well-being during symptomatic phases. This symptomatic assistance may help patients cope more steadily with symptom fluctuations and may assist with maintaining functional stability. The medication is commonly used across conditions characterized by periods of heightened symptoms such as febrile states and systemic symptom patterns, often experienced during the common cold or influenza.

Quick Fact: Symptomatic Relief
Symptom Scope Is applied for managing mild to moderate pain and elevated body temperature (fever).
Common Scenarios Used for symptomatic relief during seasonal illness, post-immunization reactions, and episodic aches.
Patient Benefit Supports comfort and may assist with maintaining functional stability during periods of discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Day?

The population eligibility for the use of Day (Acetaminophen/Paracetamol) is strictly governed by regulatory labeling, which defines both eligible groups and absolute restrictions.

Absolute Contraindications

The medicine must not be used by patients who have a known hypersensitivity or allergy to the active substance or its excipients. It is also strictly contraindicated for individuals with severe active liver disease or severe hepatic impairment, as stated in official labeling.


Eligibility by Age and Health Status

Adults and adolescents are considered eligible for standard labeled use. Use in pediatric patients is established above specific age thresholds (e.g., ge 2 years for some forms), though certain high-strength presentations are not recommended for children under 10 years.

Conditional use is necessary for patients with impaired organ function. Those with severe renal impairment (creatinine clearance le 30 mL/min) or non-severe hepatic impairment are eligible but must exercise caution. Official documents also advise caution for individuals with alcoholic liver disease or conditions leading to glutathione depletion, such as chronic malnutrition.


Pregnancy and Lactation

Use during pregnancy is permitted if clinically needed and is restricted to the lowest effective dose for the shortest duration. Use while breastfeeding is generally permitted, as the regulatory profile confirms the substance is not excreted in clinically significant amounts.

What should I know about interactions with other medicines?

Day Interactions with other medicines and products

The potential for interactions must be carefully considered when combining Day with other medicinal products. The components of this product, acetaminophen and phenylephrine, are associated with several specific interaction risks.

Contraindicated Combinations

  • Monoamine Oxidase Inhibitors (MAOIs): Use of this product is strictly contraindicated with MAOIs (a class of medicines for depression, psychiatric conditions, or Parkinson's disease), or within two weeks of stopping MAOI therapy. The combination with phenylephrine can cause a severe, sudden rise in blood pressure (hypertensive crisis).

Other Clinically Significant Interactions

  • Other Acetaminophen-Containing Products: Concomitant use with any other medicine containing acetaminophen (paracetamol) must be avoided to prevent surpassing the maximum daily dose and risking serious liver toxicity. This includes prescription and over-the-counter combination products.
  • Blood Thinners (Anticoagulants): Regular, daily use of acetaminophen over a prolonged period may increase the anticoagulant effect of warfarin and other vitamin K antagonists, raising the risk of bleeding. Dosage adjustments and close monitoring by a healthcare provider may be necessary.
  • High Blood Pressure Medicines: Phenylephrine, a decongestant, is a vasoconstrictor and may reduce the effectiveness of medicines used to control high blood pressure, such as beta-blockers or certain alpha-adrenergic blockers.
  • Sedating Medicines: Although phenylephrine is non-sedating, co-administration with other medicines that cause central nervous system depression, such as sedatives or tranquilizers, requires caution.

Food and Substance Interactions

  • Alcohol: Consumption of alcoholic beverages must be avoided. The combination of alcohol with acetaminophen significantly increases the risk of severe, potentially fatal, liver damage.

Mechanism of Action

Molecular Target and Binding

Day is a selective molecular modulator. Its action begins with high-affinity binding to the A 1 receptor, a transmembrane protein primarily expressed on the surface of osteoclast precursor cells. This specific interaction establishes the primary biological target of the compound.


Intracellular Cascade (NF-kappaB Inhibition)

The binding of Day to the A 1 receptor triggers a complex intracellular signaling event. This event involves the phosphorylation of key signaling proteins, which ultimately results in the inhibition and decreased nuclear translocation of the NF-kappa B pathway. This NF-kappa B inhibition represents the core mechanistic cascade of Day.


Cellular Consequence

The suppressed NF-kappa B activity leads to a reduced expression of factors required for osteoclast maturation and activation. This fundamental change in signaling alters osteoclast differentiation signaling and function, a key system-level physiological consequence relevant to bone homeostasis.

Dosage and Administration Information

How to Use Day (Acetaminophen/Paracetamol): Administration Guidelines

Administration of Day (Acetaminophen/Paracetamol) follows specific, label-based parameters focused on the method, frequency, and maximum allowable dose.

Administration Scope

Feature Standard Guideline
Route of Administration Approved methods include Oral (most common), Rectal (via suppository), and Intravenous (IV) (via infusion, typically for hospital use).
Dosing Schedule The standard adult single dose is typically 650 mg or 1,000 mg. The Maximum Total Daily Dose from all sources is strictly limited to 4,000 mg (4 grams) in a 24-hour period.
Frequency Dosing is administered on an as-needed basis for symptoms, with a required interval of 4 to 6 hours between successive doses.
Preparation Certain forms, such as granules or effervescent tablets, must be fully dissolved in the required volume of liquid prior to consumption.
Special Conditions Extended-release tablets must be swallowed whole and should not be crushed or chewed, as this compromises the intended release kinetics.

Use Protocol

Usage of Day is intended for a short-term course; over-the-counter use is generally limited to no more than 10 days for pain or 3 days for fever. Pediatric dosing is explicitly based on body weight (mg/kg) rather than fixed adult doses, with specific maximums detailed in the prescribing information. For patients with impaired renal function, the dose interval is prolonged to prevent accumulation. This structured protocol ensures the medicine is used within the parameters specified on the label.

Recent Clinical Evidence

Day: Recent Clinical Evidence

The clinical evaluation of Day (Acetaminophen/Paracetamol) contributes to the broader evidence landscape. This research primarily involves short-term, controlled studies used in research exploring how symptoms change over defined time intervals. The overview below describes the kind of evidence that exists, adhering to the principle that evidence highlights what is known—and what is still uncertain.


Evidence for Use in Acute Pain Relief

The agent was studied for its use in conditions characterized by fluctuating or episodic manifestations of mild to moderate pain (e.g., headache, dental, and menstrual pain). Research examined patient-reported outcomes in Randomized Controlled Trials (RCTs) compared against placebo. Studies monitored the time to onset of relief and duration of the observed effects, tracking outcomes related to physical discomfort. Findings describe patterns observed in the studies, and the evidence structure for this short-term use is broadly categorized as High. However, outcomes related to long-term use for chronic pain are not well characterized by RCTs.


Evidence for Use in Fever Reduction

The research base for the agent’s use in fever reduction (antipyresis) is also extensive, built upon numerous short-term RCTs. These studies examined temporary physiological imbalance in individuals with elevated body temperature. Researchers monitored changes measured during the study period in body temperature, along with the time to onset of the effect. The evidence structure for this function is generally categorized as High. However, comparative evidence is sometimes mixed regarding the exact magnitude of temperature reduction when evaluated against certain other antipyretic agents.


Research Gaps and Follow-up Limitations

The agent was evaluated in studies involving specific populations, including children and older adults, contributing to the body of evidence for these groups. Despite this, the research is predominantly characterized by limited follow-up durations. The duration of measured outcomes beyond the immediate, acute phase is not fully established by RCTs, and data for certain groups remain insufficient. Furthermore, clinical heterogeneity—the variation in symptoms studied—is a Research Limitation Frame documented across large reviews.

Key Studies & References Acetaminophen (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Day (FAQ)

Q: Does Day interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Official warnings state that use with other products containing acetaminophen is discouraged to prevent exceeding the maximum daily limit, a factor known to increase the risk of severe liver damage. While it may be included in some combination products with other types of pain relievers, official product information suggests consulting a healthcare professional regarding all pain medications being taken.

Q: How long does it typically take for the intended effects of Day to become noticeable?

A: Regulatory information indicates that the onset of effect is typically observed within a short time frame, usually less than an hour, after consumption. The peak effect, which represents the maximum relief reported in studies, is generally reached around one to two hours after the dose.

Q: Can Day be used safely by adults who are over the age of 65?

A: Regulatory assessment generally indicates that geriatric-specific issues do not contraindicate the use of acetaminophen. However, specific cautions are listed for older adults with certain pre-existing conditions, such as severe liver or kidney issues, as the drug's processing may be altered with age.

Q: What food or drinks are listed as potential interactions or should be avoided while taking Day?

A: The safety labeling includes a specific warning that consuming three or more alcoholic drinks per day is associated with a significantly increased risk of severe liver damage. Although specific foods are not broadly restricted, patients are instructed to consult a healthcare professional regarding all substances, including certain foods or tobacco use, that might affect the drug.

Q: What potential issues might arise if Day is used for a much longer period than the initial duration described?

A: Regulatory information indicates that use exceeding the labeled duration may be a factor in potential liver damage. For over-the-counter use, if pain persists for more than 10 days or fever lasts more than 3 days, official guidelines direct that the medication must be discontinued and a healthcare professional consulted.

Q: Is Day approved and available in major international markets outside of the US/EU?

A: Yes, as the substance is internationally known as Paracetamol. Its inclusion on the World Health Organization (WHO) Model List of Essential Medicines confirms its global recognition for essential care and its wide availability across major international markets.

Q: Does the time of day a person takes Day affect its therapeutic effectiveness?

A: The medication is typically taken on an as-needed basis with a required interval between doses. Its therapeutic effectiveness primarily depends on maintaining the appropriate dosing interval to manage symptoms, rather than the specific time of day it is taken.

Q: What is the known frequency of allergic reactions to the ingredients in Day?

A: Post-marketing surveillance reports indicate that cases of hypersensitivity and anaphylaxis, including life-threatening events, have occurred. Severe skin reactions, such as SJS and TEN, are also noted in regulatory documents, with some classifications reporting them to occur rarely.

Q: What is the typical patient expectation for relief or improvement while on Day?

A: Studies and official information indicate that the onset of symptom relief is typically observed within a short time frame after administration. Maximum relief is usually achieved when the drug reaches its peak concentration around one to two hours after the dose.

Q: Where can a patient find the complete, official prescribing information for Day?

A: The complete, official prescribing information, also known as the full regulatory label, can be found on government databases in countries where the drug is approved. Examples include the NIH DailyMed and the FDA website under the drug’s generic name, Acetaminophen.

Q: Is Day categorized as a controlled substance by regulatory health agencies?

A: Regulatory classification states that acetaminophen, when used as a single-ingredient product, is not listed as a controlled substance under U.S. regulatory acts. However, combination products that include acetaminophen with certain opioid ingredients are classified as controlled substances.

Q: Do regulatory documents mention any potential effects of Day on a person's ability to drive?

A: Because acetaminophen alone is generally not associated with sedative or tranquilizing effects, regulatory documents typically do not contain a specific warning about the effect on a person's ability to drive or operate machinery.

Q: What is the current status of the generic version availability for Day?

A: As the active ingredient is Acetaminophen (Paracetamol), a generic version is widely available under its non-proprietary chemical name. Many different manufacturers offer FDA-approved generic equivalents.

Q: What is the expected duration that the active ingredients of Day stay in the body?

A: The medication is dosed every 4 to 6 hours due to its relatively short duration of action. It is known to be rapidly absorbed and distributed throughout the body. Detailed pharmacokinetic data, which describes the drug's path, is available in the official prescribing information.

Q: What are the known interactions between Day and common vitamin or herbal supplements?

A: Specific interactions with every common vitamin and herbal supplement are generally not detailed in the official labeling. However, official regulatory documents instruct patients to inform their healthcare professional of all drugs, vitamins, and supplements they are taking to identify potential interactions.

Q: What steps are generally recommended if a potential drug-drug interaction is suspected?

A: In the event of a suspected serious interaction or accidental overdose, regulatory warnings direct that the medication must be discontinued and emergency medical attention or consultation with a healthcare provider must be sought immediately.

Q: Under what safety classifications is Day listed by the FDA or other governing bodies?

A: The official labeling provides a detailed safety analysis for its use in specific populations, which defines its overall safety profile. This includes detailed information for Pregnancy, Lactation, Pediatric Use, and Geriatric Use.

Q: Is there any documented risk of physical dependence or withdrawal described in Day’s regulatory information?

A: Acetaminophen alone is not classified as having a risk of physical dependence or requiring gradual tapering for discontinuation. This risk is typically associated with combination products that contain opioid ingredients, not with the active ingredient of Day.

Q: Is Day usage compatible with routine vaccinations or standard laboratory tests?

A: Official information does not typically address compatibility with routine vaccinations. While the drug may affect the results of certain laboratory tests, this is generally limited to specific tests like the acetaminophen level test, which is performed only when overdose is suspected.

Q: How quickly is Day metabolized by the body?

A: The drug is known to be rapidly absorbed from the gastrointestinal tract and then quickly distributed throughout the body before being processed (metabolized) by the liver. Full details on the rate of metabolism and elimination are provided in the official pharmacokinetic section.

Q: Does official information suggest any need for blood tests to monitor Day's use?

A: Routine blood tests are not typically suggested to monitor the regular use of acetaminophen. An acetaminophen level test is usually only performed by a healthcare provider when overdose is suspected to diagnose potential toxicity.

Q: Are there any special instructions for Day if a patient needs to have an upcoming surgery?

A: Regulatory documents for combination products may contain warnings, such as not using them immediately before or after heart surgery. Patients are generally advised to inform their surgical team and all healthcare providers of every medication they are taking before any procedure.

Q: Why is Day sometimes referred to as a 'once-daily' medication?

A: While the standard immediate-release product of Day is typically dosed every 4 to 6 hours, some extended-release or high-strength products of acetaminophen are specially formulated and labeled to be taken less frequently. This may lead to the 'once-daily' description.

Q: What steps do regulatory agencies take to monitor the long-term safety of a drug like Day?

A: Regulatory agencies rely on continuous post-marketing surveillance and the collection of post-marketing reports (pharmacovigilance) to gather additional safety data on a drug after it is approved. This ongoing monitoring can result in official updates to the drug's labeling over time.

Q: What are the signs that Day may not be working as expected based on study results?

A: Official labeling states that the medication must be discontinued and professional consultation is required if symptoms get worse. Furthermore, official labeling indicates that professional consultation is required if pain persists for more than 10 days or if fever lasts for more than 3 days.

Q: What is the process for regulatory bodies to re-evaluate the safety of a drug like Day?

A: Regulatory bodies routinely review the safety of medications based on new clinical trial data and information gathered from post-marketing reports. This formal re-evaluation process can result in the issuance of new warnings or significant updates to the product's labeling to ensure continued safe use.

How should Day be stored and disposed of?

Storage Conditions

Day (Acetaminophen/Paracetamol) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be kept in its original container with the cap tightly closed to protect it from excess heat and moisture. It is required to keep the medication out of the sight and reach of children using safety closures and secure storage locations.


Disposal Instructions

Do not flush unneeded Day down the toilet (unless specifically instructed for the formulation). Unused or expired medication should be disposed of by following official guidelines. The recommended methods are utilizing a local drug take-back program or securely disposing of the product in the household trash after mixing it with an undesirable substance like dirt or coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Day found in:

A-Z Index: